INSULIN-LIKE GROWTH-FACTORS IN BREAST AND PROSTATIC-CANCER

被引：7

作者：

HELLE, SI

LONNING, PE

机构：

[1] Dept. Therapeut. Oncol./Radiophysics, University of Bergen, Haukeland Hospital

来源：

关键词：

D O I：

10.1677/erc.0.0020153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IGF-I and IGF-II are both potent mitogens to breast and prostatic carcinoma cells. Evidence suggests that the disposition of IGF-I is different in patients suffering from advanced breast and prostatic carcinoma when compared with healthy controls. Steroid hormones and endocrine manipulation used in the treatment of breast and prostatic carcinomas may influence the plasma concentration of IGF-I and its binding proteins. However, due to the complex regulation of IGF bioavailability, it is difficult to evaluate the impact of alterations in IGFBPs. Further studies are warranted to evaluate the influence of hormone treatment on IGF-I, IGF-II and their binding protein in plasma and, in particular, in tumour tissue from patients suffering from breast and prostatic carcinomas. While most studies so far have evaluated the influence of short-term hormone therapy on the disposition of IGF-I, it would be of particular interest to look at the effect of long-term treatment, and to evaluate possible alterations in the IGF system in relation to the emergence of resistance to endocrine therapy.

引用

页码：153 / 169

页数：17

共 140 条

[131]

Stolfi R., Parisi A.M., Natoli C., Iacobelli S., Avanced breast cancer: Response to somatostatin, Anticancer Research, 10, pp. 203-204, (1990)

[132]

Tannenbaum G.S., Gurd W., Lapointe M., Pollak M., Tamoxifen attenuates pulsatile growth hormone secretion: Mediation in part by somatostatin, Endocrinology, 130, pp. 3395-3401, (1992)

[133]

Torrisi R., Pensa F., Orengo M.A., Catsafados E., Ponzani P., Boccardo F., Costa A., Decensi A., The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients, Cancer Research, 53, pp. 4769-4771, (1993)

[134]

Vennin P., Peyrat J.P., Bonneterre J., Louchez M.M., Harris A.G., Demaille A., Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer, Anticancer Research, 9, pp. 153-156, (1989)

[135]

Weissberger A.J., Ho K.K., Lazarus L., Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women, Journal of Clinical Endocrinology and Metabolism, 72, pp. 374-381, (1991)

[136]

Yee D., Cullen K.J., Paik S., Perdue J.F., Hampton B., Schwartz A., Lippman M.E., Rosen N., Insulin-like growth factor II mRNA expression in human breast cancer, Cancer Research, 48, pp. 6691-6696, (1988)

[137]

Yee D., Paik S., Lebovic G.S., Marcus R.R., Favoni R.E., Cullen K.J., Lippman M.E., Rosen N., Analysis of insulin-like growth factor I expression in malignancy: Evidence for a paracrine role in human breast cancer, Molecular Endocrinology, 3, pp. 509-517, (1989)

[138]

Young C.Y.-F., Montgomery B.T., Andrew P.E., Qui S., Bilhartz D.L., Tindall D.J., Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP, Cancer Research, 51, pp. 3748-3752, (1991)

[139]

Zapf J., Schmid C., Guler H.P., Waldvogel M., Hauri C., Futo E., Hossenlopp P., Binoux M., Froesch E.R., Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF-I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia, Journal of Clinical Investigation, 86, pp. 952-961, (1990)

[140]

Zhao Y., Escot C., Maudelonde T., Puech C., Rouanet P., Rochefort H., Correlation between mannose-6-phosphate/IGFII receptor and cathepsin D RNA levels by in situ hybridization in benign and malignant mammary tumours, Cancer Research, 53, pp. 2901-2905, (1993)

← 5 6 7 8 9 10 11 12 13 14 →